1. Introduction {#sec1}
===============

RNA interference (RNAi) is a natural antiviral defense mechanism in plants, fungi, invertebrates, and, under specific conditions, in mammals ([@bib6]; [@bib26]). Antiviral RNAi comes about via a sequence-specific binding of small interfering RNAs (siRNAs) to viral mRNAs or genomic RNAs, resulting in their degradation or translational repression. In general, siRNA is prone to fast degradation with RNases, and the delivery to the target cells might be difficult. A number of chemical modifications introduced to different positions in the siRNA (sense, antisense, or both strands) have been tested to improve siRNA stability and reduce off-target activities ([@bib1]; [@bib2]; [@bib4]; [@bib5]; [@bib8]; [@bib31]; [@bib7]).

Instead of chemical synthesis and post-synthesis hybridization of RNA oligonucleotides, we produce high-quality molecules for RNAi using viral RNA polymerases and recombinant *Giardia* Dicer enzyme ([@bib12]). This results in a swarm of 25-bp-long Dicer-substrate siRNAs (DsiRNAs) ([@bib13]; [@bib23]), which can cover several kbp sequence of the target ([@bib18]; [@bib16]; [@bib10]). When introduced into a cell, such siRNAs are processed by the endogenous Dicer, which enhances the RNAi potency and efficacy ([@bib11]). In the enzymatically synthesized siRNA swarms, each individual siRNA species is present only in low concentrations, diluting out the potential off-target effects ([@bib12]). The siRNA swarm contains predominantly 5′-monophosphates as only the single siRNAs originating from the very ends of the produced dsRNA molecules contain the 5′-triphosphate moiety, which could induce innate immunity responses. The swarm, comprising of numerous different siRNAs against the target, also widens the antiviral spectrum ([@bib19]; [@bib10]) and minimizes the potential of emergence of viral variants resistant to a single siRNA.

We have previously generated three antiviral siRNA swarms against herpes simplex virus type 1 (HSV-1) mRNAs encoding essential viral proteins, including glycoprotein B (*UL27*), the infected cell protein 8 (ICP8; *UL29*), and ICP27 (*UL54*) ([@bib23]; [@bib19]). The siRNA swarm targeting mRNA of HSV single-stranded DNA binding protein ICP8, encoded by the *UL29* gene, harbors most pronounced antiviral effect ([@bib19]) and induces only minimal non-specific cellular responses ([@bib23]). The HSV *UL29*-derived siRNA swarm elicits modest IFN-λ1 (IL-29), IFN--λ2/3, ISG54, and TLR3 expression ([@bib20]). However, the observed slight activation of innate immune responses did not cause a decrease in cell viability ([@bib23]; [@bib20]). The anti-HSV-UL29 siRNA swarm also controlled HSV infection in mice and inhibited local virus replication in corneal epithelia *in vivo* ([@bib21]).

Here, we set up an enzymatic production method for modified DsiRNAs using T7 DNA-dependent RNA polymerase (DdRp), phi6 RNA-dependent RNA polymerase (RdRp) and *Giardia* Dicer. Using this method, we produced UL29-specific siRNA swarms harboring 2′-fluoro-modifications in the ribose moieties of uridine, adenosine or cytidine residues. The incorporated fluoro-modifications generally improved siRNA stability. The 2′-F-siRNA swarms were well tolerated by cells and had enhanced HSV-specific antiviral activity compared to unmodified siRNA swarms.

2. Materials and methods {#sec2}
========================

2.1. Enzymatic synthesis of siRNA swarms and their purification {#sec2.1}
---------------------------------------------------------------

The 653 bp sequence of the *UL29* gene from HSV-1 prototype strain (17+) (GenBank **[JN555585.1]{.ul}**, nucleotides 59,302 to 59,954) was PCR amplified to produce a DNA template for ssRNA production ([@bib23]) using primers UL29_T7_Rev (5′-*[TAATACGACTCACTATAGGG]{.ul}*CGCAACTTTCGCAATCAAT-3′) and UL29_phi6_Fwd (5′-*[GGAAAAAAA]{.ul}*ATGATGGCCGTAAGGGTGT-3′); underlined italics are recognition sequences of T7 DdRp and phi6 RdRp, respectively. The PCR product was converted into ssRNA by incubation with four canonical nucleoside triphosphates (NTPs; Thermo Fisher Scientific, \#R0481) and T7 DdRp. The produced ssRNA (1 μg) was subsequently incubated for 6 h at 30 °C with 0.8 μg Phi6 RdRp and a 1 mM NTP mixture, including both canonical and selected sugar-modified NTPs (TriLink Biotechnologies, \#N-1007, 2′-fluoro-2′-dATP; \#N-1008, 2′-fluoro-2′-dCTP; \#N-1009, 2′-fluoro-2′-dGTP; \#N-1010, 2′-fluoro-2′-dUTP; \#N-1017, 2′-O-Methyl-GTP; or \#N-1018, 2′-O-Methyl-UTP) to produce dsRNAs. The generated dsRNA molecules were processed to swarms of 25-bp-long duplexes with in-house produced *Giardia intestinalis* Dicer ([@bib23]; [@bib21]). The siRNA molecules were purified by anion-exchange chromatography on a CIMac QA column (BIA Separations, Slovenia, 110.5113--1.3) using an ÄKTApurifier FPLC system (GE Healthcare) ([@bib24]) at the Instruct-HiLIFE Biocomplex unit (University of Helsinki). The same protocol was used to produce non-specific unmodified control siRNA swarms from a 413 bp long sequence of *Escherichia coli lacI* gene in pET32b vector using primers: Fwd_pET32b_1581: 5′-*[TAATACGACTCACTATAGGG]{.ul}*CTGCCTGCACTAATGTTCC-3′ and Rev_pET32b_1983: 5′-*[GGAAAAAAA]{.ul}*TCGTCGTATCCCACTACC-3'. As confirmed with BLASTn, the selected control sequence has no significant similarities with human, herpesviral or mouse transcriptomes. The 88 bp dsRNA was produced as described previously ([@bib9]).

2.2. RNA stability {#sec2.2}
------------------

Generated siRNAs were treated with RNase A (\#EN0531; Thermo Fisher) under the conditions suitable for dsRNA degradation: 1 μg siRNA was incubated with 0.1 μg of RNase A in 20 μl of 0.1 × SSC buffer (20 × SSC: 3 M sodium chloride + 0.3 M sodium citrate in water, pH 7.0) at room temperature for 15 min. The reactions were stopped by addition of 2.5 μl of 10 × loading dye \[50% glycerol, 40 mM EDTA pH 8.0, 0.1% bromphenol blue (w/v), 0.1% xylene cyanol\] and immediately frozen at −70 °C. The reaction products and equivalent amounts of undegraded siRNA were analyzed by electrophoresis on a 2.5% (w/v) agarose gel containing 0.2 μg/ml EtBr in Tris-acetate-EDTA (TAE) buffer at 90 V, 200 mA, 1 h. The RNAs were visualized with ChemiDoc Touch Imaging System (Bio-Rad) and the band intensities measured using Fiji ([@bib25]). The relative amount of undegraded siRNA was calculated according to the formula: a%=(S~RNaseA~ × 100)/S~untreated~, where S~RNaseA~ is a density of RNaseA-treated siRNA and S~untreated~ is a density of the equivalent amount of untreated sample.

2.3. Cells and virus {#sec2.3}
--------------------

An astrocytoma-glioma cell line (U373MG) obtained originally from ATCC (Manassas, VA) was used. The line has been subsequently reclassified as U251 human glioblastoma, but referred here as U373MG to ensure continuity with our previous studies ([@bib20], [@bib19]; [@bib23]). U373MG cells were maintained in DMEM with 10% heat inactivated fetal bovine serum (FBS) and 2 mM L-glutamine at 37 °C, 5% CO~2~. Vero cells (ATCC), used for plaque titration, were maintained in M199 medium with 5% FBS.

Green fluorescent protein (GFP)-expressing HSV-1 strain, HSV-1 (17+)Lox-P~mCMV~GFP (abbreviated here as HSV-1-GFP), originally received from prof. Beate Sodeik (MHH Hannover Medical School, Germany), was used for antiviral studies ([@bib27]; [@bib14]) and propagated as previously described ([@bib23]).

2.4. Transfection {#sec2.4}
-----------------

The U373MG cells were transfected on 96-well plates with either modified or unmodified siRNA swarms, 88 bp dsRNA or water (mock transfection) using Lipofectamine RNAiMAX (\#13778-150; Invitrogen, Carlsbad, CA) according to the manufacturer\'s forward transfection protocol ([@bib23]). Depending on the experiment, the cells were transfected with 1--10 pmols of RNA per well, which is equivalent to a concentration of 10--100 nM. All experiments were repeated at least twice with three or more biological replicates each.

2.5. Cellular viability {#sec2.5}
-----------------------

Cellular viabilities in siRNA treatments were assessed 48 h post transfection (hpt) with CellTiter-Glo (\#G7571; Promega, Madison, WI) luminescent assay ([@bib23]; [@bib30]). The luminescence was quantified with VICTOR Nivo Multimode Plate Reader (PerkinElmer, Waltham, MA). Viability of more than 80% compared to mock- and untreated cells was considered acceptable.

2.6. Quantitation of innate immunity responses by RT-qPCR {#sec2.6}
---------------------------------------------------------

The total cellular RNA was extracted from siRNA-treated U373MG cells at 8, 24, and 48 hpt with TRI Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer\'s protocol. The RNA was processed to complementary DNA using RevertAid H Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA) with random hexamer primers (Thermo Fisher Scientific) after treatment with DNAse (Thermo Fisher Scientific) ([@bib23]; [@bib20], [@bib19]).

Quantitative PCR (qPCR) was performed with Rotor-Gene Q, as previously described ([@bib17]). The GAPDH housekeeping mRNA values of the corresponding sample were used for normalization of mRNA expression levels. The mRNA expression of interferon beta (*IFN-β*) ([@bib22]), lambda 1 (*IL-29; IFN-λ1*) ([@bib19]), interferon stimulated gene 54 (*ISG54*) ([@bib23]), and GAPDH ([@bib18]) was quantified using previously published primer sequences.

2.7. Quantitation of antiviral efficacy {#sec2.7}
---------------------------------------

The RNA- or control-treated cells were challenged with a clinically relevant infectious dose of HSV-1-GFP at 1000 plaque forming units (pfu) in 100 μl per well \[multiplicity of infection (MOI) ≈ 0.06\] at 4 hpt in 96-well plates as before ([@bib19]). At 44 h post infection (hpi), the culture supernatant was collected, and the viral titer was determined by plaque titration on Vero cells in 96-well plates.

2.8. Live-cell imaging {#sec2.8}
----------------------

The HSV-1-GFP strain enabled fluorescent imaging of the virus infection and thus also of the antiviral effect. The live cell imaging was performed 48 hpt with EVOS Auto FL (Thermo Fisher Scientific) with the whole plate scan program, keeping the imaging parameters equal throughout the scan.

2.9. Statistical analysis {#sec2.9}
-------------------------

Statistical analysis was conducted with SPSS Statistics 26.0.0.0. (IBM, Armonk, NY). Statistical significances were calculated with Mann-Whitney\'s non-parametric *U* test comparing two independent groups.

3. Results {#sec3}
==========

3.1. Phi6 RdRp can use 2′-F-dNTPs as substrate to produce 2′-F-dsRNA for dicer reaction {#sec3.1}
---------------------------------------------------------------------------------------

We tested the capability of phi6 RdRp to utilize 2′-F-dNTPs and 2′-OMe-NTPs in the dsRNA synthesis. HSV *UL29* gene-specific ssRNA, produced using T7 DdRp, was used as a template for the phi6 RdRp-catalyzed dsRNA synthesis. Initially, the reactions were done by replacing one of the canonical NTPs in the reaction mixture with the corresponding modified NTP. Although dsRNA synthesis was not effective in the presence of 2′-OMe-modified NTPs ([Fig. S1](#appsec1){ref-type="sec"}) and the quality of the dsRNA product was somewhat compromized in the presence of 2′-F-dGTP ([Fig. S2A](#appsec1){ref-type="sec"}), phi6 RdRp was able to produce full-length dsRNA products using 2′-F-dATP, 2′-F-dUTP, and 2′-F-dCTP substrates ([Fig. 1](#fig1){ref-type="fig"} A), suggesting that the 113 adenosines, 128 uridines, and 185 cytidines in the antisense strand of the HSV *UL29* target sequence can potentially be replaced with their fluoro-modified counterparts. Wild-type phi6 RdRp and a mutant RdRp containing substitution K→A at position 147 (K147A) were initially tested for dsRNA production. The K147A RdRp consistently provided higher dsRNA yields ([Fig. S2B](#appsec1){ref-type="sec"}) and was therefore used for the subsequent siRNA production. Complete replacement of a canonical rNTP with the corresponding 2′-F-dNTP resulted in slightly decreased yields, which was especially pronounced when all three NTPs (ATP, UTP and CTP) carried the modification ([Fig. 1](#fig1){ref-type="fig"}A). Therefore, to produce siRNA swarms for the cellular experiments we used 2′-F-dATP, 2′-F-dCTP, or 2′-F-dUTP, but not their mixture. Furthermore, we set up a dsRNA synthesis reaction in which only a fraction (10%) of a given NTP was fluoro-modified ([Fig. S2](#appsec1){ref-type="sec"}). The mass spectrometry analysis confirmed that the "10% modified" dsRNA products contained 2′-fluoro-modified nucleotides ([Fig. S3](#appsec1){ref-type="sec"}). Furthermore, the *Giardia* Dicer could process the produced UL29-2′-F-dsRNA into a swarm of Dicer-substrate 2′-F-siRNAs ([Fig. 1](#fig1){ref-type="fig"}B).Fig. 1**Enzymatic production and stability of fluoro-modified dsRNA and siRNA.** (A) DsRNA synthesis reactions using 2′-F-dNTPs. Identical dsRNA synthesis reactions were carried out in parallel, and equal amounts from the reactions were analyzed by agarose gel electrophoresis. In the phi6 RdRp-catalyzed dsRNA synthesis reaction, unmodified canonical ATPs, CTPs or UTPs were replaced with 2′-F-dATPs (100% F-A), 2′-F-dCTPs (100% F-C), or 2′-F-dUTPs (100% F-U), respectively, or all the three NTPs were replaced with the corresponding 2′-F-dNTPs (100% F-A-C-U). Input ssRNA was loaded as a control (second well). Since the number of CMPs in the sequence is significantly higher than that for AMPs or UMPs (185 vs 113 and 128, respectively), the dsRNA species containing 2′-F-CMPs (or all the three 2′-F-NMPs) demonstrated lower electrophoretic mobility than those containing 2′-F-AMP or 2′-F-UMP. (B) Production of 2′-F-siRNAs from the 2′-F-dsRNA. *UL29*-specific 2′-F-dsRNA was digested with *Giardia* Dicer, and after chromatographic purification the samples were analyzed by agarose gel electrophoresis. 10% indicates that only a fraction of a given NTP in the original dsRNA synthesis reaction was modified and the resulting siRNA swarms are designated 10% F-A, 10% F--C, or 10% F--U. (C) RNase A sensitivity of 2′-F-siRNAs. Samples of unmodified and modified siRNAs were treated with RNase A for 15 min followed by the reaction termination and agarose gel electrophoresis. An equivalent amount of the untreated samples were also loaded on the gel. Densitometric analysis of agarose gels from five independent RNase A treatments was carried out and percentages of undegraded siRNAs from total input siRNA amounts were calculated. The data are presented as mean ± S.D. Asterisks indicate a statistically significant difference from the unmodified control, p ≤ 0.05.Fig. 1

3.2. Stability, cytotoxicity and antiviral efficacy of the 2′-F-siRNA swarms {#sec3.2}
----------------------------------------------------------------------------

### 3.2.1. Stability of the 2′-F-siRNA swarms {#sec3.2.1}

RNase A treatment in low salinity conditions was performed to assess sensitivity of the 2′-F-siRNA swarms to RNase. Under the conditions used, about 50% of the unmodified siRNA was degraded ([Fig. 1](#fig1){ref-type="fig"}C), whereas fluoro-modifications in the uridine and cytidine residues significantly enhanced the stability of the siRNAs.

### 3.2.2. Modified 2′-F-siRNA swarms are well tolerated *in vitro* {#sec3.2.2}

Cellular toxicity of the 2′-F-siRNA swarms was assessed using U373MG cells in 96-well plates. Cells were transfected with each of the HSV-specific *UL29*-gene derived-2′-F-siRNA swarms, an unmodified UL29-siRNA swarm, a non-specific siRNA swarm derived from *E. coli lacI* gene, a cytotoxic 88-bp-long control dsRNA, or water. The viability of the cells was assessed 48 hpt with luminescent assay ([Fig. 2](#fig2){ref-type="fig"} ). Transfections with the 2′-F-siRNA swarms resulted in similar levels of cellular viability to that with unmodified UL29-siRNA swarms, with the exception of the fully 2′-F-dCTP modified swarm, which was significantly less tolerated than the unmodified siRNA swarm at 50 and 100 nM. Nevertheless, all the 2′-F-siRNA swarms were well tolerated, with relative cellular viability consistently higher than 80% at doses relevant for antiviral applications. Hence, 2′-F-modifications had no effect on tolerability of the siRNA swarms in the studied concentration range. The UL29-targeting siRNA swarms did not display increased cytotoxicity in comparison to the non-specific siRNA swarm, targeting a non-relevant bacterial sequence. The 88 bp dsRNA used as a toxic control resulted in a clear decrease in cell viability at 10 nM concentration ([Fig. 2](#fig2){ref-type="fig"}). The cytotoxicity profile of the modified siRNA swarms was confirmed with non-cancerous human corneal epithelial cells, in which only the fully 2′-F-dCTP modified swarm was significantly less tolerated than the unmodified siRNA swarm ([Fig. S4](#appsec1){ref-type="sec"}).Fig. 2**Viability of U373MG cells treated with 2′-F-siRNA swarms.** U373MG cells were transfected with the indicated siRNA swarms at the concentration range of 12.5--100 nM. The antisense strand of the modified siRNA swarms was fully (referred to as 100%) or partially (referred to as 10%) modified containing either 2′-F-dAMP, 2′-F-dCMP or 2′-F-dUMP as the modified nucleotide (10% or 100% F-A, F--C or F--U, respectively). 88-bp-long phi6-derived dsRNA with known cytotoxicity was used as a control RNA, at a concentration of 10 nM. The viability of the cells was quantified at 48 hpt and shown as relative viability compared to mock- and untreated samples. The error bars represent the standard deviation of the mean from two separate experiments with 3--5 biological replicates each. Significant difference to the unmodified UL29-specific swarm is marked with asterisks (\*: p ≤ 0.05, \*\*: p ≤ 0.01, \*\*\*: p ≤ 0.001).Fig. 2

### 3.2.3. Fluoro-modifications increase antiviral efficacy of enzymatically produced UL29-siRNA swarms {#sec3.2.3}

The antiviral efficacy of the UL29-2′-F-siRNA swarms was quantified at 48 hpt by plaque titration from culture supernatants of HSV-1-GFP-infected U373MG cells. Before infection, cells were treated with HSV-targeted modified or unmodified UL29-siRNA swarms, a non-specific siRNA swarm, water (mock-treated), or left untreated ([Fig. 3](#fig3){ref-type="fig"} ). After treatment with the unmodified UL29 siRNA swarm, the viral titer was reduced at least three orders of magnitude compared to the untreated samples ([Fig. 3](#fig3){ref-type="fig"}A). The antiviral effect of the UL29-2′-F-siRNA swarms was even more pronounced, resulting in a five orders of magnitude reduction in HSV titer ([Fig. 3](#fig3){ref-type="fig"}B). Compared to treatment with the non-specific siRNA swarm, treatment with the modified and unmodified UL29 siRNA swarms resulted in a significant decrease of titer (p = 0.00000000165 and p = 0.000000178, respectively), confirming the sequence specificity of the antiviral effects ([Fig. 3](#fig3){ref-type="fig"}A). Furthermore, treatment with the UL29-2′-F-siRNA swarms in comparison with the unmodified counterparts resulted in significantly lower titers (p = 0.018) ([Fig. 3](#fig3){ref-type="fig"}A) and an extensive decrease of viral shedding (p = 0.000001) ([Fig. 3](#fig3){ref-type="fig"}C). The difference in antiviral efficacy between the 10% and 100% modified swarms was non-significant ([Fig. 3](#fig3){ref-type="fig"}A). Nonetheless, the 2′-F-siRNA swarms harboring modifications in cytidine or adenosine residues, i.e. 2′-F-dCMP-siRNA and 2′-F-dAMP-siRNA swarms respectively, yielded significantly higher antiviral potency compared to those having uridine modifications (2′-F-dUMP-siRNA), when using the unmodified UL29-siRNA swarm as a reference ([Fig. 3](#fig3){ref-type="fig"}B). The 10% modified 2′-F-dUMP-siRNA swarm was the only UL29-2′-F-siRNA swarm that did not show improved antiviral efficacy in comparison with the unmodified UL29-swarm ([Fig. 3](#fig3){ref-type="fig"}B).Fig. 3**Antiviral activity of siRNA swarms is improved by 2′-F-dNMP modifications.** U373MG cells were infected with 1000 pfu of HSV-1-GFP (MOI≈0.06) at 4 h after treatment with each of the UL29-2′-F-siRNA swarms (50 nM), unmodified UL29-siRNA swarm (50 nM) or non-specific swarm (50 nM). The guide strand of modified siRNA swarms was fully (100%) or partially (10%) modified and contained 2′-F-dAMP, 2′-F-dCMP or 2′-F-dUMP as the modified nucleotide (10% or 100% F-A, F-C or F-U, respectively). The controls were transfected with water only (mock-treated) or were left untreated. At 48 hpt, the culture supernatants were collected for quantitation of the virus (A, B, and C), and live cell imaging was performed (D). **(A)** Viral titer (pfu/ml) was determined from the supernatant samples by plaque titration. The samples treated with partially modified (10%) 2′-F-siRNA swarms (A, C, or U), and those treated with fully (100%) modified 2′-F-siRNA swarms were grouped for statistical analysis. The error bars represent standard deviation of the mean from two separate experiments with at least three replicate samples of all individual treatments and controls (N = 15--33 or N = 6--12, respectively). The significance of the changes is shown against both the non-specific swarm as well as the mock- and untreated samples (\*\*\*, p ≤ 0.001). The significant changes against a group of comparison are marked with \# (\#: p ≤ 0.05, ns: non-significant). **(B, C)** Viral shedding quantitated from the culture supernatants is shown for each individual siRNA swarm (B) or collectively for the modified siRNA swarms (C). The fold change of viral titer is presented in comparison with the untreated samples. The efficacies of the siRNA swarms, with the indicated modified nucleotides, are presented separately (N = 13--18) in panel B and collectively (N = 96) in panel C. The mean and standard deviation (shown with a horizontal line and a box, respectively) for each sample group represent five separate experiments (N = 13--96). The diamonds illustrate the individual samples. Significant changes against the unmodified UL29-specific swarm are marked with asterisks (\*: p ≤ 0.05, \*\*: p ≤ 0.01, \*\*\*: p ≤ 0.001, ns: non-significant). **(D)** Representative fluorescent images of the HSV-1-GFP -infected cells with the indicated siRNA swarm or control treatments were taken at 48 hpt. The scale bar represents 1000 μm.Fig. 3

The efficacy of the HSV-targeted siRNA swarms against HSV-1-GFP infection on U373MG cells was visualized by living cell fluorescent imaging at 48 hpt (at 44 hpi; [Fig. 3](#fig3){ref-type="fig"}D). The virus-derived GFP signal was prominent in infected cells, untreated or control-treated, whereas in cells pretreated with unmodified UL29-siRNAs or UL29-2′-F-siRNAs, the GFP signal could not be detected using standard imaging parameters.

3.3. Induction of innate immunity responses by 2′-F-siRNA swarms {#sec3.3}
----------------------------------------------------------------

Consistent with earlier research, transfection of 88 bp dsRNA, an immunostimulatory and cytotoxic molecule ([@bib9]), induced *IFN-β*, *IL-29* and *ISG54* expression in the transfected cells ([Fig. 4](#fig4){ref-type="fig"} ) ([@bib23]; [@bib20]). In comparison with untreated cells, the unmodified UL29 siRNA swarm induced modest *ISG54* and *IL-29* responses ([Fig. 4](#fig4){ref-type="fig"}B and C) but did not significantly alter *IFN-β* expression ([Fig. 4](#fig4){ref-type="fig"}A) at any time point. Notably, only the *ISG54* levels at 8 hpt differed significantly between the unmodified UL29 siRNA and transfection reagent alone (mock-treated) ([Fig. 4](#fig4){ref-type="fig"}C), indicating that the transfection reagent causes the majority of the responses in comparison with the untreated cells.Fig. 4**Innate immunity responses induced by 2′-F-siRNA swarms.** U373MG cells were treated with the indicated siRNA swarms (50 nM) or controls. The antisense strand of the modified siRNA swarms used was fully (100%) or partially (10%) modified containing either 2′-F-dAMP, 2′-F-dCMP or 2′-F-dUMP as the modified nucleotide (10% or 100% F-A, F--C or F--U, respectively). The expression levels of interferon beta (*IFN-β*; panel A), interferon lambda-1 (*IFN-λ1*, *IL-29*; panel B) and interferon-stimulated gene 54 (*ISG54*; panel C) were quantified at 8 hpt (black bars), 24 hpt (dark grey bars) or 48 hpt (light grey bars) by RT-qPCR. The expression levels, normalized to housekeeping gene *GAPDH*, are presented on a logarithmic scale. The means and standard deviations, from two separate experiments with at least four repeat samples, are presented. Significantly higher induction of *IFN*s and *ISG*s in comparison to the unmodified UL29 siRNA swarm treatment is marked with asterisks (\*: p ≤ 0.05, \*\*: p ≤ 0.01, \*\*\*: p ≤ 0.001) and significantly lower induction with \# (\#: p ≤ 0.05, \#\#: p ≤ 0.01, \#\#\#: p ≤ 0.001). If no p-value is shown, the difference to the unmodified UL29-specific swarm is not significant.Fig. 4

2′-F-dUMP- and 2′-F-dCMP-siRNAs induced higher *IFN-β, IL-29* and *ISG54* expression compared to unmodified UL29-siRNA swarm, particularly at the earliest time point ([Fig. 4](#fig4){ref-type="fig"}). Innate immunity signaling induced by 2′-F-dAMP-siRNA swarms and that by the unmodified UL29 siRNA were at equal levels, or even lower. Overall, the induction of interferon signaling by modified or unmodified siRNA swarms was not extensive (only ca. 10-fold compared to mock- and untreated cells).

4. Discussion {#sec4}
=============

We have previously reported a novel enzymatic approach to synthetize large pools of siRNA molecules, which we refer to as siRNA swarms. The antiviral siRNA swarms directed aginst the current target of choice, the *UL29* gene of HSV-1, have previously demonstrated their efficacy against circulating pathogenic HSV strains *in vitro* and corneal infection *in vivo*, unveiling their potential as antiviral drugs. In the current study, we pursued the modification of the RNAs using nucleotides with 2′-modified ribose, in order to further enhance the antiviral potency and stability of the siRNA preparations. Eventually, we are able to report successful enzymatic incorporation of 2′-F-dNTP nucleotides to biologically active dsRNA molecules. All 2′-F-siRNA swarms were well tolerated and highly effective against HSV-1 *in vitro*. The observed enhanced antiviral efficacy of the 2′-F-siRNA swarms was unrelated to the elicited cellular innate immunity responses, proving the sequence specificity of the modified siRNAs.

We produced siRNA swarms, in which either all or a fraction of adenosines, cytidines or uridines were replaced by 2′-F-dNMPs. Replacement of a 2′-OH group of ribose with a fluorine has been shown to stabilize RNA molecules against nucleases ([@bib15]). SiRNAs are primarily degraded by RNase A ([@bib29]), which recognizes the 2′-OH of pyrimidine nucleosides for cleavage ([@bib3]). Therefore, a common strategy is to modify all pyrimidines ([@bib7]) to increase the siRNA stability. Accordingly, substitution of the canonical CMPs or UMPs by the corresponding 2′-F-dNMPs resulted in a significant increase in siRNA stability in our experiments ([Fig. 1](#fig1){ref-type="fig"}C).

Conventionally, modifications are introduced into RNA molecules using chemical solid phase synthesis. Some wild-type or mutant DdRps of autographiviruses (T7, Syn5) can be used for enzymatic synthesis of single-stranded 2′-F-RNAs ([@bib28]; [@bib32]) which may be further hybridized to produce dsRNA. We demonstrate here that bacteriophage phi6 RdRp efficiently utilizes 2′-F-dNTPs allowing enzymatic production of perfectly duplexed dsRNAs without the often error-prone post-synthesis hybridization. Similarly, to other wild-type bacteriophage polymerases ([@bib28]; [@bib32]), phi6 RdRp did not tolerate 2′-OMe modifications ([Fig. S2](#appsec1){ref-type="sec"}).

All of the modified siRNA swarms were non-toxic for U373MG cells at the relevant antiviral concentrations. The findings were reproducible in human corneal epithelial cells ([Fig. S4](#appsec1){ref-type="sec"}), which represent another potential target tissue for antiviral therapy of diseases caused by HSV-1. Furthermore, modified swarms had higher antiviral activity than the unmodified swarm, as demonstrated by the significant reduction of viral titer in plaque assays. Notably, there was no difference between siRNA swarms containing only a fraction of modified dNMPs and those containing all modified dCMPs, dUMPs, or dAMPs in the antisense strand ([Fig. 3](#fig3){ref-type="fig"}). The antiviral effect of siRNAs containing only a fraction of modified dUMPs was not statistically different from the unmodified siRNA swarm. Interestingly, a higher stability to nucleases of siRNA swarms containing 2′-F-dUMPs or 2′-F-dCMPs did not translate into higher antiviral efficacy than those with 2′-F-dAMPs.

The immunostimulatory potential of 2′-F-dAMP-siRNAs resembled that of the unmodified siRNA swarm and was thus minimal. At the early time point (8 hpt), 2′-F-dUMP-siRNA and 2′-F-dCMP-siRNA swarms induced slightly higher expression of *IFN-β*, *IL-29*, and *ISG54* than the unmodified siRNA, implying that their antiviral activity at earlier time points might be partly non-specific and related to the stimulation of the innate immune response. However, 2′-F-dAMP-siRNA swarms demonstrated enhanced antiviral efficacy in comparison with the unmodified swarm, but similar immunostimulatory activity. Therefore, antiviral 2′-F-dAMP-siRNA swarm is a promising candidate for further *in vivo* studies with HSV. The elevated potency in combination with the existing benefits of the siRNA swarm approach offers also a new, potential approach for therapy of virus infections lacking treatment so far, including novel emerging viruses, such as SARS-CoV-2.
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